Journal of Intellectual Property Rights

Open Access Open Access  Restricted Access Subscription Access

Patent Waiver on Covid Vaccine: Access for all or Global Supply Crisis?


Affiliations
1 School of Law, UPES, Dehradun, Uttarakhand — 248 007,, India
 

The Coronavirus disease 2019 or COVID-19, pandemic has transpired disastrous effects in the world in multiple forms ranging from the high death tolls to the steep fall in global economy. Even so, it had managed to provide a silver lining in the form of unanimity of researchers from several disciplines, who united to contribute blood, sweat and tears to present to the world the miracle of science- vaccines. One can only imagine the extent of investment which has gone into development of the few vaccines we have today. In fact the research continues to be in full swing, with the hope and zest to better. While every country fights the pandemic with vigor, it is the pharmaceutical R&D which is expected of breakthrough discoveries as a solution. Where the pressure to succeed is tremendous, millions invested and no option to fail is it not justified to expect and deserve patent for the same. This paper will dwell into the justification of patent over Covid-19 vaccines, the ongoing debate over patent waiver and analyze whether the waiver will in fact facilitate greater access and affordability of vaccines or prove to be an impediment for global supply.

Keywords

Patent Waiver, Covid-19, Vaccine, World Trade Organization, Intellectual Property Rights.
User
Notifications
Font Size

  • Liu D X, Lang Jia Q & Fung T S, Coronavirus-229e,-Oc43,- Nl63 and Hku1, Reference Module in Life Sciences, (2020) 428.

  • Liu Kunmeng, Zixuan Gu, et. al., Global landscape of patents related to Human Coronavirus,International Journal of Biological Sciences, 17(6)(2021) 1588–1599, doi: 10.7150 /ijbs.58807

  • Fan Wu. et al., A new coronavirus associated with human respiratory disease in China, Nature 579 (2020) 265–269, https://doi.org/10.1038/s41586-020-2008-3

  • Coronaviruses: Diseases and Conditions, National Institute of Allergy and Infectious Diseases, https://www.niaid.nih. gov/diseases-conditions/coronaviruses (accessed on 14 September 2021).

  • Moreira J S, How did we develop a COVID-19 vaccine so quickly?, Medical News Today, 15 December 2020, https://www.medicalnewstoday.com/articles/how-did-wedevelop-a-covid-19-vaccine-so-quickly (accessed on 14 September 2021).

  • SaifL J, Animal Coronavirus vaccines: Lessons from SARS, Developmental Biology (Basel) (2004) 129.

  • Tizard I R, Vaccination against Coronaviruses in domestic animals, Vaccine, 38 (2020) 5123.

  • Tung Thanh Le et. al., The COVID -19 vaccine development landscape, Nature Reviews: Drug Discovery,19 (2020) 305, https://www.nature.com/articles/d41573-020-00073-5.

  • World Trade Organization, Developing and delivering COVID-19 vaccines around the world (2020) 4, https://www.wto.org/english/tratop_e/covid19_e/vaccine_rep ort_e.pdf(accessed on 11 July 2022).

  • Laslett P (ed.), Locke: Two Treatises of Government (Cambridge University Press), 1988.

  • Muhamad K M H et. al., Justifications of Intellectual Property Rights: A discussion on Locke and Hegel’s Theories, Journal Hukum Novelty, 11 (2020) 114.

  • World Health Organization, Working for Global Equitable Access to COVID-19 Vaccines, COVAX, https://www. who.int/initiatives/act-accelerator/covax.

  • Association for Molecular Pathology v Myriad Genetics Inc., 569 U.S. 576.

  • Campaign for access to essential medicines, India and South Africa Proposal for WTO Waiver from Intellectual Property Protections for COVID-19 Related Medical Technologies,18November 2020, https://msfaccess.org/sites/ default/files/2020-11/COVID_Brief_WTO_WaiverProposal_ ENG_v2_18Nov2020.pdf.

  • Maxmen A, In shock move, US backs waiving patents on COVID vaccines, Nature,6May 2021, https://www. nature.com/ articles/d41586-021-01224-3.

  • Council for Trade Related Aspects of Intellectual Property Rights, World Trade Organisation, Waiver From Certain Provisions of The Trips Agreement for the Prevention, Containment and Treatment of Covid-19, Doc: IP/C/W/669/Rev.1, 25 May 2021.

  • Siripurapu A, Thedebate over a patent waiver for Covid-19 vaccines: What to know, Council on Foreign Relations, 26 May 2021, https://www.jstor.org/stable/resrep33370 (accessed on 15 September 2021).

  • The Marrakesh Agreement Establishing the World Trade Organisation, Article IX.3

  • Feichtner I, Thewaiver power of the WTO: Opening the WTO for political debate on the reconciliation of competing interests, EuropeanJournal of International Law 20 (2009) 615.

  • The Marrakesh Agreement Establishing the World Trade Organisation, Article IX.3 (b).

  • The Marrakesh Agreement Establishing the World Trade Organisation, Article IX.4.

  • EC – Bananas III (Ecuador, Guatemala, Honduras, Mexico and the United States v European Union) [2008] WTO Appellate Body Rep. WT/DS27/AB/R, Para. 185.

  • Ranjan P, The Case for Waiving Intellectual Property Protection For Covid-19 Vaccine, Observer Research Foundation, (April 2021) 456.

  • General Council, Waiver Concerning Kimberley Process Certification Scheme for Rough Diamonds, WTO Doc: WT/L/518 (15 May 2003).

  • World Trade Organisation, Decision Removes Final Patent Obstacle to Cheap Drug Imports, Press/350/Rev. 1, (23 August 2003).

  • Trade Related Aspects of Intellectual Property Rights, Article 31.

  • Trade Related Aspects of Intellectual Property Rights, Article 31(f).

  • Trade Related Aspects of Intellectual Property Rights, Article 31(h).

  • Correa C M, Implementation of Paragraph 6 of the Doha Declaration on the TRIPS Agreement and Public Health, World Health Organization,Doc:WHO/EDM/PAR/2004.4 (April 2004), Para 3.

  • The Marrakesh Agreement Establishing the World Trade Organisation,, Article IX.3, IX.4.

  • Mercurio B, WTO waiver from intellectual property protection for COVID-19 vaccines and treatments: A critical review, Virginia Journal of International Law, March 2021.

  • 't Hoen EF, Veraldi J, Toebes B, Hogerzeil H V, Medicine procurement and the use of flexibilities in the Agreement on Trade-Related Aspects of Intellectual Property Rights, 2001- 2016, Bull World Health Organisation, 96 (3) (March 2018) 185-193, doi: 10.2471/BLT.17.199364. Epub 2018 Feb 5. PMID: 29531417; PMCID: PMC5840629.

  • A Timeline of US Attacks on India’s Patent Law & Generic Competition, Access Campaign: Medicine Sans Frontier (January 2015), https://msfaccess.org/sites/ default/files/ 201810/IP_Timeline_US%20pressure%20on%20India_Sep %202014_0.pdf.

  • Bajaj V & Pollack A, India orders bayer to license a patented drug, NY Times, 12 March 2012.

  • WTO, IP rules amended to ease poor countries’ access to affordable medicines, 2017, News Items, 23 January 2017.

  • Trade Related Aspects of Intellectual Property Rights, amendment made on 23 January 2017.

  • Astra Zeneca, Astra Zeneca takes next steps towards broad and equitable access to oxford university’s potential COVID19 vaccine, 4 June 2020.

  • Thambisetty S, Vaccines and Patents: How self-interest and artificial scarcity weaken human solidarity, LSE British Politics and Policy, 9 February 2021, https://blogs.lse.ac.uk/ politicsandpolicy/vaccines-and-patents/.

  • Editorial, A patent waiver on COVID vaccines is right and fair, Nature, 25 May 2021, https://www.nature.com/ articles/d41586-021-01242-1.

  • Fletcher E R, World Trade Organization enters COVID pandemic fray with dispute brewing over patent rights, Health Policy Watch, 14 October 2020, https://healthpolicywatch.news/world-trade-organization-enters-covidpandemic-fray-with-dispute-brewing-over-patent-rights/ (accessed on 15 September 2021).

  • Mercurio B, The IP waiver for COVID-19: Bad policy, bad precedent, IIC International Review of Industrial Property and Copyright Law, (24 Jun 2021) 1.

  • Phillips N, The coronavirus is here to stay- here’s what that means, Nature, 590 (2021) 382.


Abstract Views: 179

PDF Views: 116




  • Patent Waiver on Covid Vaccine: Access for all or Global Supply Crisis?

Abstract Views: 179  |  PDF Views: 116

Authors

Latika Choudhary
School of Law, UPES, Dehradun, Uttarakhand — 248 007,, India
Hardik Daga
School of Law, UPES, Dehradun, Uttarakhand — 248 007,, India

Abstract


The Coronavirus disease 2019 or COVID-19, pandemic has transpired disastrous effects in the world in multiple forms ranging from the high death tolls to the steep fall in global economy. Even so, it had managed to provide a silver lining in the form of unanimity of researchers from several disciplines, who united to contribute blood, sweat and tears to present to the world the miracle of science- vaccines. One can only imagine the extent of investment which has gone into development of the few vaccines we have today. In fact the research continues to be in full swing, with the hope and zest to better. While every country fights the pandemic with vigor, it is the pharmaceutical R&D which is expected of breakthrough discoveries as a solution. Where the pressure to succeed is tremendous, millions invested and no option to fail is it not justified to expect and deserve patent for the same. This paper will dwell into the justification of patent over Covid-19 vaccines, the ongoing debate over patent waiver and analyze whether the waiver will in fact facilitate greater access and affordability of vaccines or prove to be an impediment for global supply.

Keywords


Patent Waiver, Covid-19, Vaccine, World Trade Organization, Intellectual Property Rights.

References